Literature DB >> 12477574

Local secretion of parathyroid hormone-related protein by an osteoblastic osteosarcoma (UMR 106-01) cell line results in growth inhibition.

G M F Pasquini1, R A M Davey, P W M Ho, V P Michelangeli, V Grill, S J Kaczmarczyk, J D Zajac.   

Abstract

Parathyroid hormone-related protein (PTHrP) has been implicated as being important in the growth of tumor cells responsive to the peptide. We utilized a rat osteoblastic osteosarcoma cell line, UMR 106-01, which has PTHrP receptors and a PTHrP-responsive adenylate cyclase/cAMP messenger system, to produce a modified cell line that overexpresses PTHrP. The human PTHrP cDNA sequence was transfected by electroporation into UMR 106-01 cells and the stable cell lines UMR-36 and UMR-34 were established. The modified cell line, UMR-36, had increased levels of PTHrP mRNA compared with control cell lines and secreted PTHrP into the culture medium at levels of 0.01-0.1 pmol/10(7) cells in 12 h. The secreted peptide was biologically active as indicated by its ability to activate adenylate cyclase. The number of UMR-36 cells following 9 days in culture was reduced by up to 80% compared with control lines, which was associated with decreased (3)H-thymidine incorporation into genomic DNA. Addition of 1000-fold excess of the PTHrP antagonist, PTHrP(7-34), to UMR-36 cells resulted in the escape of growth inhibition and increased rate of growth. In vivo, tumors derived from UMR-36 cells were smaller in size compared with tumors derived from control cells. In conclusion, increased autocrine secretion of, and responsiveness to, PTHrP results in inhibited growth kinetics of an osteoblast-like bone tumor cell line in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477574     DOI: 10.1016/s8756-3282(02)00872-4

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  7 in total

Review 1.  A review of clinical and molecular prognostic factors in osteosarcoma.

Authors:  Jonathan C M Clark; Crispin R Dass; Peter F M Choong
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-27       Impact factor: 4.553

Review 2.  The aging spine: new technologies and therapeutics for the osteoporotic spine.

Authors:  Joseph M Lane; Michael J Gardner; Julie T Lin; Marjolein C van der Meulen; Elizabeth Myers
Journal:  Eur Spine J       Date:  2003-10-08       Impact factor: 3.134

3.  The molecular pathogenesis of osteosarcoma: a review.

Authors:  Matthew L Broadhead; Jonathan C M Clark; Damian E Myers; Crispin R Dass; Peter F M Choong
Journal:  Sarcoma       Date:  2011-04-13

4.  Fluoride levels and osteosarcoma.

Authors:  Simmi Kharb; Ravindra Sandhu; Zile Singh Kundu
Journal:  South Asian J Cancer       Date:  2012-10

Review 5.  Parathyroid hormone/parathyroid hormone-related peptide regulate osteosarcoma cell functions: Focus on the extracellular matrix (Review).

Authors:  Dragana Nikitovic; Rafaela-Maria Kavasi; Aikaterini Berdiaki; Dionysios J Papachristou; John Tsiaoussis; Demetrios A Spandidos; Aristides M Tsatsakis; George N Tzanakakis
Journal:  Oncol Rep       Date:  2016-08-01       Impact factor: 3.906

6.  Parathyroid hormone receptor 1 (PTHR1) is a prognostic indicator in canine osteosarcoma.

Authors:  Awf A Al-Khan; Judith S Nimmo; Mourad Tayebi; Stewart D Ryan; James O Simcock; Raboola Tarzi; Charles A Kuntz; Eman S Saad; Michael J Day; Samantha J Richardson; Janine A Danks
Journal:  Sci Rep       Date:  2020-01-31       Impact factor: 4.379

7.  Continuous and intermittent exposure of neonatal rat calvarial cells to PTHrP (1-36) inhibits bone nodule mineralization in vitro by downregulating bone sialoprotein expression via the cAMP signaling pathway.

Authors:  Suzan A Kamel; John A Yee
Journal:  F1000Res       Date:  2013-03-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.